Sol-Gel Will Host Gorlin Syndrome Investor Event Oct 14
The company will discuss the therapeutic potential and safety profile of SGT-610 in a presentation to investors.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you generally trust corporate announcements regarding new drug development pipelines?
Sol-Gel Technologies, based in Ness Ziona, Israel, will host a Key Opinion Leader investor event on October 14, 2026, in New York City. The session will focus on the disease burden of Gorlin Syndrome and the research-stage development of the topical hedgehog inhibitor SGT-610.
Why it matters
The company aims to address the lack of current therapeutic options for Gorlin Syndrome through the development of SGT-610. The event highlights a potential shift toward topical treatments that may offer safer side-effect profiles than systemic oral alternatives.
SGT-610 utilizes a 2% concentration of patidegib gel, designed as a topical hedgehog inhibitor. This mechanism is being evaluated to potentially provide an improved safety profile compared to existing oral hedgehog inhibitors used for basal cell carcinoma.
The players
Sol-Gel Technologies
A dermatology company based in Ness Ziona, Israel, specializing in topical drug delivery and dermatological therapeutics.
The details
SGT-610 is a topical formulation targeting the hedgehog signaling pathway, a biological mechanism essential for embryonic development that is often aberrantly activated in certain cancers. By applying this as a topical gel rather than an oral medication, the company aims to inhibit pathway activity locally in the skin while limiting systemic exposure. This research-stage approach is intended to mitigate the side effects commonly associated with systemic hedgehog inhibitors.
Timeline
September 30, 2026: Company announced the upcoming event.
October 14, 2026: The event begins at 12:00 p.m. ET in New York City.
The Tech Race
SGT-610 positions itself as a specialized alternative to existing oral hedgehog inhibitors used to treat basal cell carcinoma. This research program aims to overcome the systemic toxicity barriers that have historically limited the widespread use of the oral class of these inhibitors.
The October 14, 2026, event will be accessible to the public via a live webcast on the Sol-Gel Investor Relations website at 12:00 p.m. ET. Prospective in-person attendees must email the company to register, as SGT-610 remains a research-stage therapy not yet available for clinical use.
The takeaway
Investors and clinicians should monitor the October 14 event for updates regarding the safety profile of SGT-610. The company will release a replay of the presentation and supporting materials following the conclusion of the event.
Further reading
For more on the current landscape of experimental dermatological treatments, visit the Biotech section.
Live Poll
Do you generally trust corporate announcements regarding new drug development pipelines?
